KT
HRTX icon

Kevin Tang’s Heron Therapeutics HRTX Stock Holding History

Kevin Tang’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$783 Hold
760
– – 100% 1
2023
Q2 		$882 Hold
760
– – 100% 1
2023
Q1 		$1.15K Hold
760
– – 100% 1
2022
Q4 		$1.9K Hold
760
– – 100% 1
2022
Q3 		$3K Hold
760
– – 100% 1
2022
Q2 		$2K Hold
760
– – 0.26% 2
2022
Q1 		$4K Hold
760
– – 0.39% 2
2021
Q4 		$7K Hold
760
– – 0.62% 2
2021
Q3 		$8K Sell
760
-2,685
-78% -$32.7K 0.83% 2
2021
Q2 		$53K Hold
3,445
– – 4.91% 2
2021
Q1 		$56K Hold
3,445
– – 5.21% 2
2020
Q4 		$73K Sell
3,445
-14,713
-81% -$256K 7.27% 2
2020
Q3 		$269K Hold
18,158
– – 21.76% 2
2020
Q2 		$267K Sell
18,158
-3,130
-15% -$51.4K 20.71% 2
2020
Q1 		$250K Sell
21,288
-297,714
-93% -$5.6M 19.87% 2
2019
Q4 		$7.5M Buy
319,002
+281,003
+740% +$6.22M 88.83% 1
2019
Q3 		$703K Hold
37,999
– – 24.97% 2
2019
Q2 		$706K Sell
37,999
-946
-2% -$18.9K 24.13% 2
2019
Q1 		$952K Buy
+38,945
New +$1.02M 38.16% 2

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Kevin Tang's HRTX Position: Q3 2023 in Review

Kevin Tang held its Heron Therapeutics (HRTX) position steady in Q3 2023 at 760 shares worth $783. The position accounts for 100% of the portfolio, ranked #1.

Kevin Tang first reported a position in HRTX in Q1 2019 and has held it in 19 quarters since. The position peaked at $7.5M in Q4 2019. 141 funds tracked by Wall St. Rank hold HRTX as of Q3 2023.

  • Kevin Tang held 760 shares of Heron Therapeutics worth $783 as of Q3 2023.
  • Kevin Tang left its Heron Therapeutics share count unchanged in Q3 2023.
  • Heron Therapeutics made up 100% of Kevin Tang's portfolio in Q3 2023, its #1 holding.
  • Kevin Tang first reported a position in Heron Therapeutics in Q1 2019 and has held it in 19 quarters since.
  • Kevin Tang's Heron Therapeutics position peaked at $7.5M in Q4 2019.
  • 141 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2023.

Based on Kevin Tang's 13F filing for Q3 2023, filed 14 Nov 2023.